# Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

> **NCT06735144** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **DRUG:** FH-006
- **DRUG:** FH-006

## Key facts

- **NCT ID:** NCT06735144
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06735144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06735144, "Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06735144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*